The corporate venturing unit of Siemens supports the US-based cancer treatment company's third round after it won Food and Drug Administration approval for one of its products.
Siemens Venture Capital, the corporate venturing division of Germany-based industrial conglomerate Siemens, has helped US-based cancer treatment company ViewRay raise a $45m round yesterday.
Siemens Venture Capital was joined by investment firms Aisling Capital and Fidelity Biosciences, which invests in healthcare on behalf of mutual fund manager Fidelity Investments as its sole limited partner, as well as venture firms Kearny Venture Partners, OrbiMed Advisors in the series C round.
ViewRay technology combines both radiotherapy and magnetic resonance imaging scans for…
